Proof‑of‑concept study investigating the role of S100P‑RAGE in nasopharyngeal carcinoma

Wang,Chengyu; Wang,Xueqiao; Han,Angxuan; Wang,Yuhao; Jiang,Hui

doi:10.3892/etm.2021.9901

Proof‑of‑concept study investigating the role of S100P‑RAGE in nasopharyngeal carcinoma

Authors:
- Chengyu Wang
- Xueqiao Wang
- Angxuan Han
- Yuhao Wang
- Hui Jiang
View Affiliations

Affiliations: Department of Otolaryngology, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China, Research Center for Clinical Medicine, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China, Department of Pathology, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China
Published online on: March 8, 2021 https://doi.org/10.3892/etm.2021.9901
Article Number: 470
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nasopharyngeal carcinoma (NPC) is an epithelial carcinoma that arises from the lining of the nasopharyngeal mucosa. The efficacy of radiation therapy is limited due to radiation resistance, particularly in the advanced stages of NPC. The S100P protein is a small isoform of the S100 protein family, which is involved in the regulation of various intracellular and extracellular processes, including proliferation, differentiation and intracellular signaling. The aim of the current study was to investigate the significance of the S100P‑RAGE axis in NPC progression. The expression levels of S100P and receptor for activated glycation end‑products (RAGE) in NPC specimens were determined by western blotting. In addition, the effect of the S100P‑RAGE axis on NPC was evaluated in vitro by proliferation and migration assays using C666‑1 cells treated with S100P or the RAGE inhibitor FPS‑ZM1. The underlying mechanism was also investigated by western blotting. The expression of S100P and RAGE was detected in clinical specimens from 15 patients with NPC and 15 patients with benign nasopharyngeal inflammation, and was observed to be higher in NPC tissues compared with inflamed tissues. Furthermore, the interaction of S100P with RAGE increased the proliferation and migration potential of C666‑1 cells, and activated mitogen‑activated protein kinase and NF‑κB signaling. These results indicate that the S100P‑RAGE axis exerts a promoting effect on the progression of NPC. Therefore therapeutic strategies targeting S100P‑RAGE merit further exploration for the treatment of NPC.

View Figures

View References

1	Tian Y, Tang L, Yi P, Pan Q, Han Y, Shi Y, Rao S, Tan S, Xia L, Lin J, et al: miRNAs in radiotherapy resistance of nasopharyngeal carcinoma. J Cancer. 11:3976–3985. 2020.PubMed/NCBI View Article : Google Scholar
2	Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y and Ma J: Nasopharyngeal carcinoma. Lancet. 394:64–80. 2019.PubMed/NCBI View Article : Google Scholar
3	Lee AW, Ng WT, Chan YH, Sze H, Chan C and Lam TH: The battle against nasopharyngeal cancer. Radiother Oncol. 104:272–278. 2012.PubMed/NCBI View Article : Google Scholar
4	Cao SM, Simons MJ and Qian CN: The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer. 30:114–119. 2011.PubMed/NCBI View Article : Google Scholar
5	Tu C, Zeng Z, Qi P, Li X, Yu Z, Guo C, Xiong F, Xiang B, Zhou M, Gong Z, et al: Genome-wide analysis of 18 epstein-barr viruses isolated from primary nasopharyngeal carcinoma biopsy specimens. J Virol. 91:e00301–e00317. 2017.PubMed/NCBI View Article : Google Scholar
6	Lam WKJ and Chan JYK: Recent advances in the management of nasopharyngeal carcinoma. F1000Res. 7(F1000)2018.PubMed/NCBI View Article : Google Scholar
7	Nakayama H, Ohuchida K, Yonenaga A, Sagara A, Ando Y, Kibe S, Takesue S, Abe T, Endo S, Koikawa K, et al: S100P regulates the collective invasion of pancreatic cancer cells into the lymphatic endothelial monolayer. Int J Oncol. 55:211–222. 2019.PubMed/NCBI View Article : Google Scholar
8	Sasahira T, Kirita T, Bhawal UK, Yamamoto K, Ohmori H, Fujii K and Kuniyasu H: Receptor for advanced glycation end products (RAGE) is important in the prediction of recurrence in human oral squamous cell carcinoma. Histopathology. 51:166–172. 2007.PubMed/NCBI View Article : Google Scholar
9	Choi J, Lee MK, Oh KH, Kim YS, Choi HY, Baek SK, Jung KY, Woo JS, Lee SH and Kwon SY: Interaction effect between the receptor for advanced glycation end products (RAGE) and high-mobility group box-1 (HMGB-1) for the migration of a squamous cell carcinoma cell line. Tumori. 97:196–202. 2011.PubMed/NCBI View Article : Google Scholar
10	Leclerc E, Fritz G, Vetter SW and Heizmann CW: Binding of S100 proteins to RAGE: An update. Biochim Biophys Acta. 1793:993–1007. 2009.PubMed/NCBI View Article : Google Scholar
11	Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, et al: RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell. 97:889–901. 1999.PubMed/NCBI View Article : Google Scholar
12	Becker T, Gerke V, Kube E and Weber K: S100P, a novel Ca(2+)-binding protein from human placenta. cDNA cloning, recombinant protein expression and Ca2+ binding properties. Eur J Biochem. 207:541–547. 1992.PubMed/NCBI View Article : Google Scholar
13	Prica F, Radon T, Cheng Y and Crnogorac-Jurcevic T: The life and works of S100P-from conception to cancer. Am J Cancer Res. 6:562–576. 2016.PubMed/NCBI
14	Arumugam T, Simeone DM, Van Golen K and Logsdon CD: S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res. 11:5356–5364. 2005.PubMed/NCBI View Article : Google Scholar
15	Liu Y, Wang C, Shan X, Wu J, Liu H, Liu H, Zhang J, Xu W, Sha Z, He J and Fan J: S100P is associated with proliferation migration in nasopharyngeal carcinoma. Oncol Lett. 14:525–532. 2017.PubMed/NCBI View Article : Google Scholar
16	Cheung ST, Huang DP, Hui AB, Lo KW, Ko CW, Tsang YS, Wong N, Whitney BM and Lee JC: Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer. 83:121–126. 1999.PubMed/NCBI View Article : Google Scholar
17	Hudson BI and Lippman ME: Targeting RAGE signaling in inflammatory disease. Annu Rev Med. 69:349–364. 2018.PubMed/NCBI View Article : Google Scholar
18	Mahmood T and Yang PC: Western blot: Technique, theory, and trouble shooting. N Am J Med Sci. 4:429–434. 2012.PubMed/NCBI View Article : Google Scholar
19	Franken NA, Rodermond HM, Stap J, Haveman J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc. 1:2315–2319. 2006.PubMed/NCBI View Article : Google Scholar
20	Sun Y, Liu WZ, Liu T, Feng X, Yang N and Zhou HF: Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Recept Signal Transduct Res. 35:600–604. 2015.PubMed/NCBI View Article : Google Scholar
21	Pramanik KC, Makena MR, Bhowmick K and Pandey MK: Advancement of NF-κB signaling pathway: A novel target in pancreatic cancer. Int J Mol Sci. 19(3890)2018.PubMed/NCBI View Article : Google Scholar
22	Huang T, Yin L, Wu J, Gu JJ, Wu JZ, Chen D, Yu HL, Ding K, Zhang N, Du MY, et al: MicroRNA-19b-3p regulates nasopharyngeal carcinoma radiosensitivity by targeting TNFAIP3/NF-κB axis. J Exp Clin Cancer Res. 35(188)2016.PubMed/NCBI View Article : Google Scholar
23	Chan AT: Current treatment of nasopharyngeal carcinoma. Eur J Cancer. 47 (Suppl 3):S302–S303. 2011.PubMed/NCBI View Article : Google Scholar
24	Yang H, Zhang G, Che X and Yu S: Slug inhibition increases radiosensitivity of nasopharyngeal carcinoma cell line C666-1. Exp Ther Med. 15:3477–3482. 2018.PubMed/NCBI View Article : Google Scholar
25	Barker HE, Paget JT, Khan AA and Harrington KJ: The tumour microenvironment after radiotherapy: Mechanisms of resistance and recurrence. Nat Rev Cancer. 15:409–425. 2015.PubMed/NCBI View Article : Google Scholar
26	Arumugam T, Simeone DM, Schmidt AM and Logsdon CD: S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem. 279:5059–5065. 2004.PubMed/NCBI View Article : Google Scholar
27	Parkkila S, Pan PW, Ward A, Gibadulinova A, Oveckova I, Pastorekova S, Pastorek J, Martinez AR, Helin HO and Isola J: The calcium-binding protein S100P in normal and malignant human tissues. BMC Clin Pathol. 8(2)2008.PubMed/NCBI View Article : Google Scholar
28	Stecca B and Rovida E: Impact of ERK5 on the hallmarks of cancer. Int J Mol Sci. 20(1426)2019.PubMed/NCBI View Article : Google Scholar
29	Sen R and Baltimore D: Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 46:705–716. 1986.PubMed/NCBI View Article : Google Scholar
30	Jiang L, Lai YK, Zhang J, Wang H, Lin MC, He ML and Kung HF: Targeting S100P inhibits colon cancer growth and metastasis by Lentivirus-mediated RNA interference and proteomic analysis. Mol Med. 17:709–716. 2011.PubMed/NCBI View Article : Google Scholar
31	Ning X, Sun S, Hong L, Liang J, Liu L, Han S, Liu Z, Shi Y, Li Y, Gong W, et al: Calcyclin-binding protein inhibits proliferation, tumorigenicity, and invasion of gastric cancer. Mol Cancer Res. 5:1254–1262. 2007.PubMed/NCBI View Article : Google Scholar
32	Beissel B, Silva ID, Pesquero JB, Russo J, Schor N and Bellini MH: S-phase reduction in T47D human breast cancer epithelial cells induced by an S100P antisense-retroviral construct. Oncol Rep. 17:611–615. 2007.PubMed/NCBI
33	Zhang YW, Zheng Y, Wang JZ, Lu XX, Wang Z, Chen LB, Guan XX and Tong JD: Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer. Epigenetics. 9:896–909. 2014.PubMed/NCBI View Article : Google Scholar
34	Tang H, Liu YJ, Liu M and Li X: Establishment and gene analysis of an oxaliplatin-resistant colon cancer cell line THC8307/L-OHP. Anticancer Drugs. 18:633–639. 2007.PubMed/NCBI View Article : Google Scholar